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Abstract
Patients with type 1 diabetes (T1D) suffer from beta-cell destruction by CD8+ T-cells that
have preproinsulin as an important target autoantigen. It is of great importance to under-
stand the molecular mechanism underlying the processing of preproinsulin into these CD8+
T-cell epitopes. We therefore studied a pathway that may contribute to the production of
these antigenic peptides: degradation of proinsulin via ER associated protein degradation
(ERAD). Analysis of the MHC class I peptide ligandome confirmed the presentation of the
most relevant MHC class I-restricted diabetogenic epitopes in our cells: the signal peptide-
derived sequence A15-A25 and the insulin B-chain epitopes H29-A38 and H34-V42. We
demonstrate that specific silencing of Derlin-2, p97 and HRD1 by shRNAs increases steady
state levels of proinsulin. This indicates that these ERAD constituents are critically involved
in proinsulin degradation and may therefore also play a role in subsequent antigen genera-
tion. These ERAD proteins therefore represent interesting targets for novel therapies aiming
at the reduction and possibly also prevention of beta-cell directed auto-immune reactions in
T1D.
Introduction
In type 1 diabetes patients (T1D), pancreatic beta cells are destroyed by autoreactive CD8+ T-
-cells that have preproinsulin as their most important target antigen [1]. The importance of
these T-cells is emphasized by their presence in insulitic lesions and in peripheral blood of T1D
patients [2, 3]. In mouse models, preproinsulin-derived peptides can be used to induce diabetes
[4], whereas blocking immune responses to preproinsulin can prevent diabetes [1]. CD8+ T-
-cells were found to recognize several different sequences within the preproinsulin protein.
Some CD8+ T-cell antigens originate from the signal sequence of preproinsulin [5], but the
majority of the epitopes identified originate from the proinsulin protein itself [1]. In view of
the dominant role of proinsulin as an autoantigen, it is of great importance to understand
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proinsulin degradation and its subsequent processing into peptides that are recognized by
CD8+ T-cells.
The hormone precursor preproinsulin is co-translationally translocated into the ER lumen.
After signal sequence cleavage and the formation of three disulfide bonds, the majority of the
proinsulin molecules exit the ER and traffic via the Golgi to secretory granules. Within these
granules, proinsulin is cleaved into the insulin A-B chain dimer and C-peptide. In response to
blood glucose levels, insulin is secreted into the extracellular environment (Fig 1, left part). In
addition to exit from the ER via the secretory pathway, proinsulin may enter the ER associated
protein degradation (ERAD) pathway (Fig 1, right part). It has been estimated that 30–50% of
all newly synthesized proteins are degraded immediately after their completion [6]. The pro-
portion of newly synthesized proinsulin that is degraded in pancreatic β-cells is unknown but,
considering the large quantities of insulin these cells secrete [7], it is very likely that significant
amounts of proinsulin are degraded.
Degradation of ER luminal and membrane proteins occurs via the ER Associated protein
Degradation (ERAD) pathway [8]. ERAD-clients are unfolded and reduced by ER-resident
chaperones and oxidoreductases and subsequently dislocated (retro-translocated) across the
ER membrane into the cytosol, where they are degraded by the proteasome. On their way to
the proteasome, proteins are ubiquitinated by E3 ligases. Several ER-membrane E3 ligases have
been identified, of which gp78 [9], HRD1 [10], TEB4 [11], TRC8 [12] and TMEM129 [13, 14]
are the most characterized. HRD1 has been implicated in the degradation of mouse proinsulin
[15]. Its yeast homologue, Hrd1p, has been suggested to form the pore through which ER lumi-
nal ERAD substrates dislocate [16, 17]. HRD1 forms complexes with the membrane proteins
Derlin-1 and Derlin-2 [18, 19] (Fig 1 inset). Although the specific role of Derlin-1 and Derlin-2
in the ERAD pathway still remains to be determined, these proteins have been found to be
essential for dislocation of several ERAD-clients into the cytosol [20, 21]. At present, it is
unknown if any of these Derlin proteins are required for the dislocation and/or degradation of
proinsulin.
For a number of degradation substrates, extraction from the ER membrane has been shown
to require the AAA-ATPase p97 (VCP) [22]. P97 shuttles substrates from the membrane to the
proteasome for degradation into smaller peptides. The resulting peptides may be reimported
into the ER lumen by the TAP transporter and may subsequently be loaded onto MHC class I
molecules for presentation to CD8+ T-cells (Fig 1, right part). In the view of the important role
of CD8+ T-cells in the etiology of T1D it is important to understand the molecular mechanism
of insulin degradation, including the role of ERAD in this process.
We recapitulate the ER stages of proinsulin biogenesis using a surrogate beta-cell as a study
model. Elution of peptides fromMHC class I molecules isolated from these cells confirms the
presentation of the most relevant MHC class I diabetogenic epitopes: the signal peptide-derived
sequence A15-A25 and the insulin B-chain epitopes H29-A38 and H34-V42. We demonstrate
in these cells that specific silencing of Derlin-2, p97 and HRD1 by shRNA increases steady
state levels of proinsulin, indicating that these ERAD proteins are involved in proinsulin degra-
dation and subsequent antigen generation.
Results
Proinsulin degradation products are loaded onto MHC class I molecules
To study the processing of proinsulin into antigenic peptides, a myelogenous leukemia cell
line, K562, that stably expresses MHC class I (HLA-A2) [23], was transduced with retroviruses
carrying the (mutant) preproinsulin gene followed by an internal ribosome entry site (IRES)
and an eGFP-encoding sequence. This resulted in a pool of eGFP-positive cells that, after
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FACS sorting, were 95% positive for eGFP (Fig 2A). To evaluate the proinsulin levels in the
K562 cells compared to pancreatic β-cells, lysates from preproinsulin-expressing K562 cells
and from human islets were loaded onto SDS-PAGE and immunoblotted for proinsulin
(Fig 2B). While proinsulin was abundantly present in the human islet cells, only a small quan-
tity was detectable in the K562 cells, indicating that proinsulin is expressed in the surrogate β-
cells, but at levels that are much lower compared to those in human islet cells.
Presentation of proinsulin-derived peptides to T-cells requires loading of the peptides onto
MHC class I molecules (Fig 1, right part). To investigate whether peptides resulting from
Fig 1. Insulin biosynthesis. Schematic representation of proinsulin synthesis, followed by either secretion or degradation. (1) Proinsulin molecules co-
translationally translocate into the ER lumen. (2) Properly folded proinsulin molecules traffic to the secretory granules. Misfolded or abundant proinsulin
molecules dislocate across the ERmembrane (3) into the cytosol, potentially assisted by HRD1, Derlin-1 or Derlin-2 and p97 (inset). Cytosolic proinsulin is
then degraded into smaller peptides by the proteasome. Proinsulin derived peptides are reimported into the ER lumen via TAP and (4) loaded onto MHC
class I molecules. These traffic to the plasmamembrane and (5) present the proinsulin-derived peptides to CD8+ T-cells.
doi:10.1371/journal.pone.0128206.g001
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proinsulin degradation also follow this pathway in our K562 cells, we affinity purified MHC
class I molecules from GFP-sorted cells. The peptide ligandome was acid-eluted from the
MHC class I molecules and analyzed by mass spectrometry. This revealed three peptides that
were derived from preproinsulin (Table 1 and Fig 2C and S1 Fig). One peptide originated from
the signal sequence (A15-A24); this peptide has been identified previously as an important
autoantigen in T1D [5]. CD8+ T-cells recognizing this epitope destroy β-cells in a glucose-
dependent fashion. The second and third peptide, H26-A38 and H34-V42, both originate from
the B-chain of proinsulin. The H34-V42 peptide has been identified as a CD8+ T-cell epitope
in diabetes-specific immune responses [24, 25]. These findings show that the preproinsulin-
expressing K562 cells produce biologically relevant epitopes recognized by diabetic CD8+ T-
-cells, which indicates that these cells may serve as a suitable model system to study the genera-
tion of these epitopes.
Fig 2. Generation of preproinsulin expressing K562 cells. (A) K562 cells were retrovirally transduced to express preproinsulin-IRES-GFP and sorted for
the GFP positive population. Flow cytometry analysis of wild-type preproinsulin-expressing cells before transduction (left panel), after retroviral transduction
but before sorting (middle panel) and after sorting (right panel). Sorting yielded a cell population that was approximately 95%GFP positive. (B) Human
pancreatic islets cells and preproinsulin-expressing K562 cells were lysed and proteins were separated on 12%Nu-PAGE. Proinsulin levels were analyzed
byWestern blot. The number of cells used to prepare the lysates is indicated. (C) Schematic representation of the preproinsulin molecule including the three
disulfide bonds. The epitopes eluted fromMHC class I molecules are depicted in red.
doi:10.1371/journal.pone.0128206.g002
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Proinsulin is degraded by the cytosolic proteasome
Pulse chase assays were used to study proinsulin maturation. K562 cells were pulse-labeled for
15 minutes with 35S-labeled methionine and cysteine and chased for the times indicated (Fig
3A). Analysis of immunoprecipitated proinsulin via SDS-PAGE revealed that the radiolabeled
preproinsulin molecules largely disappeared within two hours after synthesis. In pancreatic β-
cells, convertases catalyze the excision of the C-peptide from proinsulin resulting in the A-B
chain heterodimer [26]. Since these convertases are absent in K562 cells, proinsulin remains
unprocessed in these cells. The disappearance of proinsulin in the K562 cells can therefore
either be explained by secretion or by degradation. No radiolabeled proinsulin was detected by
immunoprecipitation from the supernatant after the two hours of chase (data not shown).
Therefore, its unlikely that secretion accounts for the complete loss of proinsulin during the
two hours chase period. Since we did not observed cell-death during the experiment either, we
hypothesized that the proinsulin molecules disappeared due to degradation.
To assess whether proinsulin is degraded in a proteasome-dependent manner, K562 cells
were treated with two compounds that inhibit the proteasome, N-Acetyl-Leu-Leu-Norleu-al
(ALLN) and Lactacystin (Lc). This resulted in a significant increase of proinsulin compared to
the DMSO (-) control (Fig 3B). Because the K562 cells showed no detectable secretion of proin-
sulin and displayed high levels of proteasome dependent degradation, these cells were used as
model system to study the proinsulin degradation pathway in more detail.
Because the signal sequence of preproinsulin targets the protein into the ER lumen co-trans-
lationally and since the proteasome resides in the cytosol, degradation of proinsulin would
require its dislocation across the ER membrane. To monitor dislocation of proinsulin, K562
cells were treated with proteasome inhibitors after which the plasma membrane was permeabi-
lized with Streptolysin O. The supernatant (soluble cytosolic fraction) was separated from the
pellet (ER lumen and membrane fractions) through centrifugation and protein content was
analyzed by Western blotting (Fig 3C). The cytosolic GFP protein appeared only in the super-
natant fraction whereas calreticulin (CRT), a soluble ER luminal protein, was solely visible in
the pellet fraction, indicating that only the plasma membrane was permeabilized while the ER
membrane remained intact. Proinsulin was exclusively detected in the pellet fraction. Because
the proinsulin that accumulates after proteasome inhibition remains in a membrane-enclosed
compartment (Fig 3C) and since we could not detect any secretion of proinsulin in our pulse
chase assays (Fig 3A), the proinsulin most likely remained within the ER lumen to await even-
tual dislocation into the cytosol and degradation by the proteasome. The finding that protea-
some inhibition results in a block in dislocation is not unique and has been observed for other
ERAD-substrates previously [27]. The fact that proinsulin was found in the ER luminal frac-
tion confirms that the proinsulin molecules enter the ER lumen initially and require dislocation
out of the ER lumen for degradation via the ERAD pathway. The observed ER-luminal accu-
mulation of proinsulin upon proteasomal inhibition suggest tight coupling of the ubiquitin-
proteasome system to the dislocation pathway.
Proinsulin degradation depends on Derlin-2, HRD1 and p97
Proteasomal degradation of proteins residing in the ER lumen occurs via the ERAD pathway.
To determine which proteins of the ERAD pathway are involved in proinsulin dislocation, we
generated a set of lentiviral vectors containing shRNAs directed against Derlin-1, Derlin-2, p97
and the ER membrane-localized E3 ligase HRD1 (Fig 1, inset). The viral vectors co-expressed a
puromycin selection gene and the mOrange protein to monitor transduction efficiency. After
seven days of selection, flow cytometry analysis showed that 95–100% of the cells were mOr-
ange-positive (Fig 4A). The shRNAs against Derlin-1, Derlin-2 and p97 caused a significant
Proinsulin Degradation via ERAD
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Fig 3. Proinsulin is dislocated into the cytosol and degraded by the proteasome. (A) K562 cells stably
expressing preproinsulin were pulse labeled with 35S-methionine and cysteine for 15 minutes and chased for
the indicated times. Immunoprecipitated proinsulin was analyzed using 15% SDS-PAGE. Quantification of
the pulse chase experiment is shown below. Gel is representative for four experiments. (B) Preproinsulin-
expressing K562 cells were treated for 3 hours with either DMSO, 100 μMALLN or 10 μM Lactacystin (Lc).
Proinsulin Degradation via ERAD
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decrease of their respective target proteins compared to a random control shRNA (Fig 4B).
Verification of HRD1 knockdown at the protein level was not possible because intracellular
HRD1 levels were too low to be detected by Western blot analysis (data not shown).
After verifying knockdown of the ERAD components, the same cell lysates were blotted for
proinsulin (Fig 4C). Derlin-1 knockdown had no clear effect on proinsulin levels. In contrast,
Derlin-2, p97 and HRD1 knockdown resulted in a strong increase of proinsulin levels. These
findings indicate that Derlin-2, HRD1 and p97 are involved in the degradation of proinsulin.
Increased expression of Derlin-2 reduces steady-state levels of
proinsulin
Because lowering protein levels of Derlin-2 resulted in increased proinsulin levels, we antici-
pated that overexpressing this ERAD component might create an opposite effect and might
promote proinsulin degradation. To test this, we overexpressed Derlin-1 and Derlin-2 in pre-
proinsulin-expressing K562 cells and subsequently monitored the relative levels of proinsulin
in these cells via Western blotting (Fig 5). Derlin-1 and Derlin-2 both showed a strong increase
in protein levels upon overexpression (Fig 5 upper panels) although lanes were loaded with an
equal amount of cellular protein (data not shown). Increase of Derlin-1 protein expression
slightly increased proinsulin levels,. Yet, overexpression of Derlin-2 resulted in decreased pro-
insulin levels (Fig 5, lower panels). In summary, knockdown and overexpression of Derlin-2
increase and decrease proinsulin protein levels, respectively, indicating that Derlin-2 has a
strong effect on the level of proinsulin degradation in K562 cells.
Derlin-2 depletion reduces proinsulin degradation
Because Western blots only reflect steady-state conditions, proinsulin degradation kinetics
were studied in a pulse chase assay. Seven days post transduction of Derlin-1 and Derlin-2
shRNAs, preproinsulin-expressing K562 cells were pulse-labeled and proinsulin degradation
was monitored in time. None of the shRNAs had a significant effect on the de novo synthesis
as indicated by the comparable proinsulin levels in the different cells directly after the pulse
(Fig 6). Knockdown of Derlin-1 had no detectable effect on proinsulin degradation (Fig 6A).
Knockdown of Derlin-2 using two different shRNAs resulted in a significant increase in proin-
sulin levels, especially after 60 and 90 minutes of chase (Fig 6B). These findings indicate that
proinsulin degradation is inhibited in K562 cells upon silencing of the Derlin-2 gene using
shRNAs.
Discussion
In view of the emerging role of proinsulin as an autoantigen in T1D, this study focuses on the
processing of proinsulin into epitopes for recognition by CD8+ cytotoxic T-cells. Proinsulin is
processed into three clinically relevant T-cell epitopes in our surrogate cells we using shRNA
gene silencing we identified Derlin-2, HRD1 and p97 to be involved in proinsulin degradation.
Cells were lysed and proteins were separated using 12% Nu-PAGE. Proinsulin levels were analyzed by
Western blot. Transferrin receptor (TFR) was blotted as a loading control. Gel is representative for four
experiments. (C) K562 cells stably expressing preproinsulin were treated for 3 hours with 100 μMALLN and
treated with Streptolysin-O to permeabilize the plasmamembrane. After separation of the cytosol
(supernatant) from the cell (pellet), protein levels for GFP (top panel), calreticulin (CRT, middle panel) and
proinsulin (PI) were analyzed using 15% SDS-PAGE andWestern blot. Gels are representative for three
experiments.
doi:10.1371/journal.pone.0128206.g003
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Eluting the MHC class I ligandome and subsequent mass spectrometry analysis revealed
that preproinsulin was processed into at least three different CD8+ T-cell epitopes in our surro-
gate beta-cells. These three specific peptide sequences are clinically relevant and their corre-
sponding CD8+ T-cells are found in T1D specific immune responses [5, 24, 25]. Furthermore,
the B10-B18 (H34-V42) epitope that we found is, albeit shorter, homologues to the mouse
Fig 4. Derlin2, p97 and HRD1 knockdown increases proinsulin steady state levels. (A) Schematic
representation of the experimental setup for the knockdown of ERAD proteins with shRNAs. Preproinsulin-
expressing K562 cells were transduced to express the respective shRNAs together with mOrange from a
bicistronic lentiviral expression vector. mOrange expression levels were analyzed by flow cytometry either
before transduction or on day 3 and day 7 after transduction; the latter includes 4 days of selection with
puromycin. Flow cytrometry analysis of a representative transduction of K562 cells is shown. (B) Proinsulin-
expressing K562 cells were transduced with the indicated shRNAs. Seven days after transduction, cell
lysates were prepared and loaded onto 12% Nu-PAGE; Derlin-1, Derlin-2 and p97 protein levels were
analyzed byWestern blot. Actin was included as a loading control. Gels are representative for three different
experiments. (C) K562 cells were transduced as described for B and proinsulin levels were analyzed by
Western blot. Actin was included as a loading control. Gels are representative for three different experiments.
doi:10.1371/journal.pone.0128206.g004
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B9-B23 epitope that is accountable for the diabetic phenotype of the non-obese diabetic
(NOD) mouse [28–30]. The list of identified preproinsulin-derived CD8+ T-cell epitopes that
give rise to a diabetes-specific immune response is dominated by sequences originating from
the B-chain of proinsulin [1]. Given that the B-chain epitopes are produced via proteasomal
degradation (Fig 1) is it not surprising that the B-chain of proinsulin harbors the majority of
the proteasomal cleavage sites predicted within the proinsulin molecule [25, 31].
Inhibition of the proteasome resulted in an increase of steady-state proinsulin levels in our
cells. The proteasomal degradation of proinsulin is not restricted to K562 cells and is in line
with previous observations in 293T cells [32], COS7 cells [15] and rat pancreatic islets [33].
Our study indicates that inhibition of the proteasome results in a block of proinsulin disloca-
tion into the cytosol. This causes an accumulation of proinsulin within a membrane-enclosed
cellular compartment, presumably the ER lumen. This tight coupling between dislocation and
degradation is also observed for MHC class I molecules after β2m depletion and proteasome
inhibition [27]. Although the reason for this tight coupling between dislocation and degrada-
tion is unknown, it may represent a mechanism to prevent accumulation of undigested protea-
some substrates in the cytosol, where they potentially may form toxic aggregates [34].
Using shRNA gene silencing we found that downregulating Derlin-2, HRD1 and p97
increased steady-state levels of proinsulin, indicating that these proteins facilitate proinsulin
degradation. Knockout of the Derlin-1 and Derlin-2 genes causes embryonic lethality in mice
[35, 36], stressing their importance for cellular functioning. Despite this importance, only a
small pool of mammalian ERAD substrates are identified that rely specifically on one the Der-
lins for their degradation, suggesting reduncency between these homologues. Proinsulin and
sonic hedgehog protein [37] are currently the only two known non-glycosylated ER luminal
ERAD-substrates that rely solely on Derlin-2 for their degradation. The fact that both
Fig 5. Derlin-2 overexpression decreases proinsulin steady state levels. K562 cells stably expressing
preproinsulin were transduced with cDNA to overexpress Derlin-1 or Derlin-2 from a lentiviral expression
vector. Seven days post transduction and selection, cell lysates were prepared and separated on 12%Nu-
PAGE. Protein levels were analyzed byWestern blot using antibodies against the indicated proteins and
quantification of PI levels is shown. Gels are representative for three different experiments.
doi:10.1371/journal.pone.0128206.g005
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substrates are non-glycosylated advocates towards a more general role for Derlin-2 in ERAD,
not restricting it to glycosylated clients as suggested previously [38].
Both Derlin-1 and Derlin-2 are found in a HRD1-containing complex, which also contains
the ERAD constituents Sel1L, Herp, VIMP (VCP interacting membrane protein) and p97 [18,
37, 39]. The degradation of proinsulin was sensitive to the down-regulation of both Derlin-2
and HRD1 but not Derlin-1. Although both Derlins are present in this complex, the interaction
reported for Derlin-2 with HRD1 appears stronger then the interaction of Derlin-1 with HRD1
[37]. Also, Derlin-2 seems the major Derlin constituent in the HRD1-complex [18]. These con-
ditions may explain that HRD1 acts in concert with Derlin-2 to dislocate and degrade ERAD-
clients rather then together with Derlin-1.
Derlin-2 and p97 have been identified in a complex with the soluble ER-luminal protein
SDF2L1. SDF2L1 was also found to bind a folding-defective mutant form of proinsulin [40].
Intriguingly, knockdown of SDF2L1 has an opposite effect to what we found for Derlin-2, since
it rather increased proinsulin degradation. The latter suggests a role for SDF2L1 in limiting the
accessibility of proinsulin to ERAD for instance by retaining proinsulin within the ER lumen to
favor its folding. This potential role for SDF2L1 as a chaperone for proinsulin fits with the
observation that SDF2L1 is present in a chaperone-complex together with several other ER-
resident chaperones [41].
The insulin producing beta-cells of T1D patients are reported to suffer from chronic ER
stress [42]. Most ERAD proteins, including Derlin-2, HRD1, p97 and SDF2L1, are upregulated
Fig 6. Derlin-2 depletion delays insulin degradation. (A) K562 cells stably expressing preproinsulin were transduced to express either nonsense shRNA
(left) or an shRNA targeting Derlin-1 (right). After pulse-labeling for 15 minutes with 35S-methionine and cysteine, cells were chased for the indicated times.
Proinsulin was immunoprecipitated from the lysates and analyzed using 15% SDS-PAGE. Quantification of the pulse chase experiment is shown on the right.
Gels are representative for two different experiments. (B) Similar as described for A but with two shRNAs targeting Derlin-2. Quantification of the pulse chase
experiment is shown on the right.
doi:10.1371/journal.pone.0128206.g006
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under ER stress conditions [10, 38, 43, 44]. This increase in ERAD-protein expression ensures
that accumulating ERAD substrates are cleared from the ER lumen and are targeted for degra-
dation. The K562 cells do not express preproinsulin endogenously and therefore probably will
display altered degradation efficiency and kinetics. But because the ERAD pathway and expres-
sion of all its constituents is conserved throughout all cell types, we expect that the degradation
route of proinsulin and its requirement of Derlin-2, p97 and HRD1 will be similar in beta-cells.
It has been widely accepted that degradation products of newly synthesized proteins are the
source for epitopes presented to CD8+ T-cells in MHC class I molecules. Decreasing proinsulin
degradation in pancreatic β-cells therefore potentially opens new avenues for treatment of type
1 diabetes, as blocking proinsulin degradation may affect the presentation of proinsulin-
derived epitopes via MHC class I molecules to CD8+ T-cells [45]. Prevention of ERAD through
small compounds like eeyarestatin may decrease proinsulin degradation [46]. The latter may
also positively influence insulin secretion because more proinsulin molecules may enter the
secretory route. The latter has been reported for rat β-cells where proteasome inhibition with
lactacystin resulted in increased insulin secretion under high glucose conditions [33].
Our study revealed that Derlin-2, p97 and HRD1 play an important role in proinsulin deg-
radation. Inhibition of these ERAD constituents may reduce the generation of insulin-derived
auto-antigens. The same time, secretion of insulin may be increased. Thus Derlin-2, HRD1 and
p97 represent potentially interesting new drug targets, opening new avenues for the treatment
and possibly also the prevention of auto-immune diabetes.
Materials and Methods
Antibodies and chemicals
Proinsulin was immunoprecipitated with guinea-pig anti insulin (Abcam). Westernblot analy-
sis was performed with the following antibodies; H86 for proinsulin (Santa Cruz), anti Derlin-
1 and Derlin-2 (MBL), anti VCP/p97 (BD transduction laboratories), anti-calreticulin (Thermo
Scientific), 1E4 for GFP (Enzo Life Sciences), anti-actin clone c4 (Millipore), H86.4 anti trans-
ferrin receptor (Roche Diagnostics). Lactacystein was obtained from Enzo Life Sciences and
ALLN (Calpain inhibitor I) from Sigma.
Constructs
Preproinsulin cDNA was subcloned into the retroviral pLZRS-IRES-eGFP vector. A Derlin-1
expression construct was kindly provided by dr. Yihong Ye (Laboratory of Molecular Biology,
NIDDK, NIH Bethesda, Maryland USA) and adjusted with side-directed mutagenisis to match
Q9BUN8.1. A Derlin-2 plasmid was obtained from plasmID (#HsCD00330204). Both Derlins
were subcloned behind the EF1α promoter in a bicistronic lentiviral expression vector contain-
ing a Zeocin resistance gene followed by T2A peptide and mAmetrine behind the hPGK pro-
motor [13]. The shRNAs targeting Derlin 1 (TRCN0000062914), Derlin 2 [23
TRCN0000128182, #2 TRCN0000130112, #3 TRCN0000147427], p97 [23 TRCN0000004251,
#2 TRCN0000004253] and HRD1 [23 TRCN0000034004, 2# TRCN0000034006] were
obtained from Sigma and subcloned behind a U6 promotor into a lentiviral expression vector
containing a puromycin resistance gene and mOrange.
Cell lines
K562 stably expressing HLA-A0201 were obtained from C Britten [23] and were maintained
in IMDM (Lonza) and HEK293T cells in DMEM (Lonza). Cell culture medium was supple-
mented with 8% fetal calf serum (Sigma) containing 100 U/ml each of penicillin and
Proinsulin Degradation via ERAD
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streptomycin (Life Technologies) and 2 mMGlutamax I (Lonza) and kept in humidified incu-
bators at 37°C containing 5% CO2.
Western blot
Proinsulin molecules from cell lysates (20 mMMES, 50 mM Tris-HCl pH 7.4, 100 mMNaCl,
1% Triton X-100, 1 mM AESBF, 5 μg/ml leupeptin) were reduced with 50 mMDTT, treated
with 100 mMN-Ethylmaleimode (NEM, Sigma) and separated using 12% NuPAGE Bis-Tris
Gels (Invitrogen). After 70 minutes of transfer at 90 V, PVDF membranes (Milipore) were
incubated for 60 minutes with 5% blotting milk in TBS (150 mMNaCl, 0.003 mM KCl, 25 mM
Tris-HCl pH 7.5) and incubated 16 hours with the indicated antibody in 1% milk in TBS con-
taining 0.05% Tween-20 (TBS-T). After extensive washing, membranes were incubated for 45
minutes with the secondary antibody in 1% milk in PBS-T and after incubation with ECL solu-
tions (Pierce) membranes were exposed to film (GE healthcare).
Viral transductions
Replication-deficient recombinant retroviruses were produced for preproinsulin expression
using the Phoenix amphotropic packaging system, as described previously [47]. After 48–96 h,
culture supernatants were harvested and filtered through a 0.45-μm-pore filter. K562 cells were
infected with 1 ml retrovirus-containing medium in tissue culture dishes coated with 12 μg/ml
RetroNectin. Transduction efficiency was examined by measuring eGFP expression and cells
were sorted to obtain a 95–100% eGFP positive population using a FACS-Ariall sorter (Becton
Dickinson). Derlin-1, Derlin-2, p97 and HRD1 overexpression and knockdown was realized by
generating replication-deficient recombinant lentiviruses via linear PEI (1 mg/ml) cotransfec-
tion of HEK 293T cells with a pSico-based lentiviral vectors encoding the gene of interest or
pKLO.1 based vector containing the shRNAs, as well as pCMV-VSVG, pMDLg-RRE, and
pRSV-REV [48]. After 48–96 h, culture supernatants were harvested and filtered through a
0.45-μm-pore filter and preproinsulin expressing K562 were transduced with 100 μl lenti-virus
containing medium during a 90 minutes spin infection at 33°C. Cells were selected with either
2 μg/ml puromycin (shRNA vectors) or 400 μg/ml Zeocin (Life Technologies) to obtain a pure
population. Transduction efficiency was analyzed using a FACSCalibur flow cytometer (Becton
Dickinson) using using FACS-DIVA (Becton Dickinson) and FlowJo (Tree Star, Ashland, OR)
software FlowJo software (TreeStar).
Pulse-chase analysis
The pulse-chase assay was performed as described before [49]. Briefly, K562-A2 cells were
starved for 15–25 min in MEM without cysteine/methionine (ICN biomedicals) supplemented
with Glutamax I (manufacturer) and were pulse-labeled for 15 min with 35S-methionine and
cysteine (EasytagTM Express Protein Labeling Mix, Perkin Elmer). Proinsulin was immunopre-
cipitated from the radiolabeled non-denaturing lysate (20 mMMES, 50 mM Tris-Cl pH 7.4,
100 mMNaCl, 1% Triton X-100, 1 mM AESBF, 5 μg/ml leupeptin) using guinea-pig anti-insu-
lin antibody. The samples were reduced with 50 mM DTT, treated with 100 mMNEM and
analyzed on 15% SDS-PA gel, prepared for fluorography, dried, and exposed to film (Kodak
Biomax MS). Quantification was done with Quantity One software (Biorad)
Peptide elution & mass spectrometry
Peptide elution was performed similar to van Lummel et al. [50]. Subsequently the HLA-
peptides were analyzed via on-line C18-nano-HPLC-MS with a system consisting of an Easy
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nLC 1000 gradient HPLC system (Thermo, Bremen, Germany), and a Q-Exactive mass spec-
trometer (Thermo). Fractions were injected onto a homemade precolumn (100 μm × 15 mm;
Reprosil-Pur C18-AQ 3 μm, Dr. Maisch, Ammerbuch, Germany) and eluted via a homemade
analytical nano-HPLC column (15 cm × 50 μm; Reprosil-Pur C18-AQ 3 um). The gradient
was run from 0% to 30% solvent B (10/90/0.1 water/ACN/FA v/v/v) in 120 min. The nano-
HPLC column was drawn to a tip of ~5 μm and acted as the electrospray needle of the MS
source. The Q-Exactive mass spectrometer was operated in top10-mode. Parameters were reso-
lution 70,000 at an AGC target value of 3,000,000, maximum fill time of 100 ms (full scan), and
resolution 35,000 at an AGC target value of 1,000,000/maximum fill time of 128 ms for MS/MS
at an intensity threshold of 78,500. Apex trigger was set to 1 to 5 seconds, and allowed charges
were 1–3. In a post-analysis process, raw data were converted to peak lists using Proteome Dis-
coverer 1.4 (Thermo). For peptide identification, MS/MS spectra were submitted to the human
IPI 3.87 database using Mascot Version 2.2.04 (Matrix Science) with the following settings:
10 ppm and 20 mmu deviation for precursor and fragment masses, respectively; no enzyme
was specified. All reported hits were assessed manually, and peptides with MASCOT scores
<35 were generally discarded.
Supporting Information
S1 Fig. MS2-spectra of the eluted peptides. Comparison of MS2-spectra of the eluted insulin
peptide candidates and their synthetic counterparts for peptide HLVEALYLV, HLC(cys)
GSHLVEA. In addition, the MS2-spectrum of peptide ALWGPDPAAA is shown. The precur-
sor mass is indicated, and the best mascot ion score. Fragments are annotated. IL = immonium
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